Pharmacogenomics: precision tool in routine prescription
YU Bing
Central Clinical School, Faculty of Medicine and Health, University of Sydney/Department of Medical Genomics, Royal Prince Alfred Hospital, Sydney NSW 2050, Australia
Abstract：Pharmacogenomics is an emerging tool to improve the efficacy and safety of drug treatment through the DNA analysis in the genes related to drug concentrations (pharmacokinetics) and drug actions (pharmacodynamics). Clinicians need to integrate the genomic data in their benefit-risk assessment and then provide the right drug to the right patient at the right time. This tool can help to prevent an ineffective treatment, select right dose and reduce adverse drug reactions that are common in the current practice under the trial-observation-adjustment model. Pharmacogenomics may have extensive impacts on unique paediatric patients to enhance a better relationship between medical professionals and affected children or their guardians and to improve the drug compliance. Clinicians should embrace the advancements in pharmacogenomics and actively participate in clinical research to identify the ancestor-related alleles and develop the population-specific gene panel. It will allow patients to enjoy more achievements in pharmacogenomics by implementing it in first line clinical practice.
Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmaco-genomic testing[J]. Clin Pharmacol Ther, 2014, 95(4):423-431.
[2]
Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital:prospective analysis of 18820 patients[J]. BMJ, 2004, 329(7456):15-19.
[3]
Weiner H, Wei B, Zhou J. Subunit communication in tetrameric class 2 human liver aldehyde dehydrogenase as the basis for half-of-the-site reactivity and the dominance of the oriental subunit in a heterotetramer[J]. Chem Biol Interact, 2001, 130-132(1-3):47-56.
O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2013, 61(4):e78-e140.
[6]
Mackenzie IS, Maki-Petaja KM, Mceniery CM, et al. Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans[J]. Arterioscler Thromb Vasc Biol, 2005, 25(9):1891-1895.
[7]
Li Y, Zhang D, Jin W, et al. Mitochondrial aldehyde dehydro-genase-2(ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin[J]. J Clin Invest, 2006, 116(2):506-511.
[8]
Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer[J]. N Engl J Med, 2013, 369(11):1023-1034.
[9]
Westover D, Zugazagoitia J, Cho BC, et al. Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors[J]. Ann Oncol, 2018, 29(suppl_1):i10-i19.
[10]
Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia[J]. J Clin Oncol, 2015, 33(11):1235-1242.
[11]
Moriyama T, Nishii R, Perez-Andreu V, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity[J]. Nat Genet, 2016, 48(4):367-373.
[12]
Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes:2018 update[J]. Clin Pharmacol Ther, 2019, 105(5):1095-1105.
[13]
Hosono N, Kato M, Kiyotani K, et al. CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection[J]. Clin Chem, 2009, 55(8):1546-1554.
[14]
Del Tredici AL, Malhotra A, Dedek M, et al. Frequency of CYP2D6 alleles including structural variants in the United States[J]. Front Pharmacol, 2018, 9:305.
[15]
Ciszkowski C, Madadi P, Phillips MS, et al. Codeine, ultrarapid-metabolism genotype, and postoperative death[J]. N Engl J Med, 2009, 361(8):827-828.
[16]
Kelly LE, Rieder M, van den Anker J, et al. More codeine fatalities after tonsillectomy in North American children[J]. Pediatrics, 2012, 129(5):e1343-e1347.
[17]
Kuehn BM. FDA:no codeine after tonsillectomy for children[J]. JAMA, 2013, 309(11):1100.
[18]
Kelly LE, Chaudhry SA, Rieder MJ, et al. A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk[J]. PLoS One, 2013, 8(7):e70073.
[19]
Lachman HM, Papolos DF, Saito T, et al. Human catechol-O-methyltransferase pharmacogenetics:description of a functional polymorphism and its potential application to neuropsychiatric disorders[J]. Pharmacogenetics, 1996, 6(3):243-250.
[20]
Froehlich TE, Epstein JN, Nick TG, et al. Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder[J]. J Am Acad Child Adolesc Psychiatry, 2011, 50(11):1129-1139.e2.
[21]
Kereszturi E, Tarnok Z, Bognar E, et al. Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children[J]. Am J Med Genet B Neuropsychiatr Genet, 2008, 147B(8):1431-1435.
[22]
Michelson D, Read HA, Ruff DD, et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD[J]. J Am Acad Child Adolesc Psychiatry, 2007, 46(2):242-251.
[23]
Gonsalves SG, Dirksen RT, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes[J]. Clin Pharmacol Ther, 2019, 105(6):1338-1344.
[24]
Ording H. Investigation of malignant hyperthermia susceptibility in Denmark[J]. Dan Med Bull, 1996, 43(2):111-125.
[25]
Litman RS, Rosenberg H. Malignant hyperthermia:update on susceptibility testing[J]. JAMA, 2005, 293(23):2918-2924.
[26]
Aaberg KM, Gunnes N, Bakken IJ, et al. Incidence and prevalence of childhood epilepsy:a nationwide cohort study[J]. Pediatrics, 2017, 139(5):e20163908.
[27]
Chung WH, Hung SI, Hong HS, et al. Medical genetics:a marker for Stevens-Johnson syndrome[J]. Nature, 2004, 428(6982):486.
[28]
Phillips EJ, Sukasem C, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine:2017 update[J]. Clin Pharmacol Ther, 2018, 103(4):574-581.
[29]
Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan[J]. N Engl J Med, 2011, 364(12):1126-1133.
[30]
Johnson JA, Caudle KE, Gong L, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing:2017 update[J]. Clin Pharmacol Ther, 2017, 102(3):397-404.
[31]
Takeuchi F, Mcginnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose[J]. PLoS Genet, 2009, 5(3):e1000433.
[32]
van den Anker J, Reed MD, Allegaert K, et al. Developmental changes in pharmacokinetics and pharmacodynamics[J]. J Clin Pharmacol, 2018, 58(Suppl 10):S10-S25.
[33]
van Leeuwen RW, Peric R, Hussaarts KG, et al. Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer[J]. J Clin Oncol, 2016, 34(12):1309-1314.
